secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2023-06-01T23:59:59+00:00
Accession:  0001493152-23-019752
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem reports Q1 preliminary: Phexxi sales up 35% to $5.8M, operating loss down 85%
--------------------------------------------------------------------------------

- Net product sales of Phexxi rose >35% to ~$5.8M in Q1 2023 from $4.3M in Q1 2022.
- Total operating expenses cut >70% to ~$9.4M vs $33.2M in prior-year quarter.
- Loss from operations decreased >85% to ~$3.6M from $28.9M a year ago.
- Company on track for quarterly EBITDA breakeven by year-end 2023.
- Regained compliance with debt covenants via May 18 reverse stock split.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315223019752/0001493152-23-019752-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315223019752/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-019752

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer